Evommune, Inc.

EVMN · Biotech · NYSE · As of 10 Sep 2026

FundamentalsNot enough data yet
ValueNot enough data yet
News flowBalanced
MomentumWeak
SafetyBalanced

Overall confidence 34/100 — few inputs available yet

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Very high (52/100) · Gap confidence 56/100Documented progress is running well ahead of market attention.

This month at a glance

AIR Score™ change: 0AIR Score™ held steady this month.

Cycle window9 Sep 2026 → 10 Sep 2026

MoversNothing moved meaningfully this month.

Evidence timeline

[8-K 2.02] Evommune, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Aug 6, 2026 · 8-K
[8-K 8.01] Evommune, Inc. — Other EventsSEC · SEC EDGAR
Jun 29, 2026 · 8-K
[8-K 2.02] Evommune, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
May 7, 2026 · 8-K
[8-K 2.02] Evommune, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Mar 5, 2026 · 8-K
[8-K 1.01] Evommune, Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
Feb 12, 2026 · 8-K
[8-K 3.02] Evommune, Inc. — Unregistered Sales of Equity SecuritiesSEC · SEC EDGAR
Feb 12, 2026 · 8-K
[8-K 2.02] Evommune, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
Dec 11, 2025 · 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.